Factors affecting visual acuity after one year of follow up after repeated intravitreal ranibizumab for macular degeneration

Factors affecting visual acuity after one year of follow up after repeated intravitreal ranibizumab for macular degeneration

Aim: Providing intravitreal ranibizumab therapy for neovascular age related macular degeneration (nARMD) is a source of increasing strain for many UK eye departments. Whilst most units attempt to adhere to the product licence of following up patients at four weekly intervals; delays in follow up app...

Full description

Bibliographic Details
Main Authors:	Gwyn Samuel Williams, Eulee Seow, Huw Evans, Muyiwa Owoniyi, Sam Evans, Christopher Blyth
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2015-07-01
Series:	Saudi Journal of Ophthalmology
Online Access:	http://www.sciencedirect.com/science/article/pii/S1319453415000296

Similar Items

Retinal ganglion cell function after repeated intravitreal injections of ranibizumab in patients with age-related macular degeneration
by: Nishimura T, et al.
Published: (2012-07-01)

Ganglion Cell Complex Evaluation in Exudative Age-Related Macular Degeneration after Repeated Intravitreal Injections of Ranibizumab
by: Andrea Perdicchi, et al.
Published: (2015-01-01)

Intravitreal Ranibizumab Therapy in Wet Type Macular Degeneration
by: Hüseyin Dündar, et al.
Published: (2014-10-01)

Effect of Repeated Intravitreal Ranibizumab and Aflibercept Injections on the Cornea in Patients with Age-Related Macular Degeneration
by: Beata Urban, et al.
Published: (2020-01-01)

Results of Intravitreal Ranibizumab Treatment for Exudative Age-Related Macular Degeneration
by: Umut Karaca, et al.
Published: (2012-01-01)

Efficiency of Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degeneration
by: Didem sahin, et al.
Published: (2015-12-01)

THE MACULAR HOLE AFTER INTRAVITREAL INJECTIONS OF RANIBIZUMAB IN A PATIENT WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION – A CASE STUDY
by: Magdalena Kal, et al.
Published: (2013-11-01)

Location of submacular hemorrhage as a predictor of visual outcome after intravitreal ranibizumab for age-related macular degeneration
by: Karagiannis D, et al.
Published: (2017-11-01)

Early changes in macular optical coherence tomography parameters after Ranibizumab intravitreal injection in patients with exsudative age-related macular degeneration
by: Nicole Antunes de Almeida, et al.
Published: (2018-02-01)

Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab
by: Rachel Hui Fen Lim, et al.
Published: (2017-03-01)

Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
by: Sam Razavi, et al.
Published: (2021-02-01)

Foveal threshold and photoreceptor integrity for prediction of visual acuity after intravitreal aflibercept on age-related macular degeneration
by: Sakai T, et al.
Published: (2018-04-01)

Correlation between improvement in visual acuity and QOL after Ranibizumab treatment for age-related macular degeneration patients: QUATRO study
by: Yuji Oshima, et al.
Published: (2021-01-01)

Systemic adverse events after intravitreal bevacizumab versus ranibizumab for age-related macular degeneration: a meta-analysis.
by: Wei Wang, et al.
Published: (2014-01-01)

Efficacy of intravitreal dexamethasone implant in persistent diabetic macular edema after primary treatment with intravitreal ranibizumab
by: Kübra Özata, et al.
Published: (2019-09-01)

Intravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumab
by: Daniel Sanju Narayan, et al.
Published: (2015-01-01)

Visual outcome of intravitreal ranibizumab for exudative age-related macular degeneration: timing and prognosis
by: Canan H, et al.
Published: (2014-01-01)

Intravitreal Ranibizumab for Diabetic Macular Edema Patients with Good Baseline Visual Acuity: A Real-Life Study
by: Abdullah Ozkaya, et al.
Published: (2017-10-01)

Cytokine and Chemokine Profile Changes in Patients with Neovascular Age-Related Macular Degeneration After Intravitreal Ranibizumab Injection for Choroidal Neovascularization
by: Sun T, et al.
Published: (2021-06-01)

Aqueous cytokine levels are associated with reduced macular thickness after intravitreal ranibizumab for diabetic macular edema.
by: Tomoyasu Shiraya, et al.
Published: (2017-01-01)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
by: Pessoa B, et al.
Published: (2021-01-01)

The effects of ranibizumab injections on fluorescein angiographic findings and visual acuity recovery in age-related macular degeneration
by: Gungel H, et al.
Published: (2014-05-01)

Genetic association with intravitreal ranibizumab response for neovascular age-related macular degeneration in Hispanic population
by: Francisco Jose Rodriguez, et al.
Published: (2019-01-01)

Visual Performance in Patients with Neovascular Age-Related Macular Degeneration Undergoing Treatment with Intravitreal Ranibizumab
by: Sarah Sabour-Pickett, et al.
Published: (2013-01-01)

The effect of vitreomacular adhesion in exudative age-related macular degeneration on the results of ranibizumab intravitreal injection
by: Suzuki H, et al.
Published: (2017-08-01)

A Case of Sustained Intraocular Pressure Elevation after Multiple Intravitreal Injection of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration
by: Hisashi Matsubara, et al.
Published: (2016-04-01)

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
by: Fouda SM, et al.
Published: (2017-03-01)

Role of ranibizumab in management of macular degeneration
by: Singh Rishi, et al.
Published: (2007-01-01)

Diabetic papillopathy with macular edema treated with intravitreal ranibizumab
by: Kim M, et al.
Published: (2013-11-01)

Visual acuity after intravitreal ranibizumab with and without laser therapy in the treatment of macular edema due to branch retinal vein occlusion: a 12-month retrospective analysis
by: Reiko Umeya, et al.
Published: (2021-10-01)

Factors affecting the efficacy of treatment and recurrence in intravitreal ranibizumab applications in neovascular age-related macular degeneration
by: Özlem Kuru, et al.
Published: (2015-06-01)

One-Year Results of Photodynamic Therapy Combined with Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration
by: Tomoko Nakamura, et al.
Published: (2012-01-01)

Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degeneration
by: Partha Biswas, et al.
Published: (2011-01-01)

Visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population
by: Basheer K, et al.
Published: (2015-05-01)

Early Responses to Intravitreal Ranibizumab in Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy
by: Wataru Matsumiya, et al.
Published: (2011-01-01)

Clinical observation of intravitreal injection of Ranibizumab for choroidal neovascularization in patients with non- age-related macular degeneration
by: Yu-Xin Li, et al.
Published: (2016-05-01)

Effects of intravitreal ranibizumab on the untreated eye and systemic gene expression profile in age-related macular degeneration
by: Michalska-Małecka K, et al.
Published: (2016-03-01)

The effect of intravitreal administration of bevacizumab on macular edema and visual acuity in age-related macular degeneration with subfoveolar choroidal neovascularisation
by: Ristić Dragana, et al.
Published: (2013-01-01)

A prospective pilot study comparing combined intravitreal ranibizumab and half-fluence photodynamic therapy with ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration
by: Williams PD, et al.
Published: (2012-09-01)

Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular Degeneration
by: David R. Griffin, et al.
Published: (2014-01-01)